Clinical Trials Sponsored by Antengene Corporation

Total 6461 results

Shanghai Antengene Corporation Limited

Terminated

A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors (REACH)

Advanced Solid Tumors

China
Antengene Corporation

Completed

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma (MARCH)

Relapse/Refractory Multiple Myeloma

China
Antengene Discovery Limited

Recruiting

A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM)

Advanced Solid Tumors | Hematological Malignancies

Australia
Shanghai Antengene Corporation Limited

Terminated

A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) (HATCH)

Myelodysplastic Syndrome

China
Shanghai Antengene Corporation Limited

Terminated

A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)

Advanced Solid Tumors

China
Antengene Corporation

Recruiting

A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL (SWATCH)

Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin Lymphoma

China
Antengene Corporation

Terminated

A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma (TOUCH)

Peripheral T-cell Lymphoma | NK/T-cell Lymphoma

China
Antengene Corporation

Active, not recruiting

A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (BENCH)

Relapsed or Refractory Multiple Myeloma

China
Antengene Corporation

Active, not recruiting

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SEARCH)

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

China
Antengene Corporation

Terminated

A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (MATCH)

Relapsed/Refractory Diffuse Large B-cell Lymphoma

China
Antengene Biologics Limited

Recruiting

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (PROBE)

Advanced Solid Tumor | Metastatic Solid Tumor | Mature B-cell Non-Hodgkin Lymphoma

United States, Australia
Antengene Therapeutics Limited

Terminated

A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma (TEACH)

Solid Tumor, Non-Hodgkin's Lymphoma

China, Taiwan
Antengene Biologics Limited

Recruiting

A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

Advanced Solid Tumors | B-cell Non-Hodgkin Lymphomas

United States
Antengene Biologics Limited

Recruiting

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors (CLINCH)

Advanced/Metastatic Solid Tumors

China, Australia
Antengene Therapeutics Limited

Terminated

Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects

Hepatocellular Carcinoma

Korea, Republic of, Taiwan, China
Antengene (Hangzhou) Biologics Co., Ltd.

Recruiting

A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Advanced Solid Tumor | Metastatic Solid Tumor | Mature B-cell Non-Hodgkin Lymphoma

China
Antengene Therapeutics Limited
Bristol-Myers Squibb

Recruiting

Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies (ERASER)

Solid Tumor | Hematological Malignancy

Australia
Antengene Therapeutics Limited
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors

Australia, China
Shanxi Bethune Hospital
Antengene Corporation

Recruiting

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Relapsed or Refractory Acute Myeloid Leukemia

China
Tong Chen
Antengene Corporation

Recruiting

Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

Central Nervous System Lymphoma

China
Sun Yat-sen University
Fudan University; Antengene Corporation

Recruiting

Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

EBV-Positive Diffuse Large B-Cell Lymphoma, Nos

China
Xia Zhongjun
Antengene Corporation

Recruiting

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
Li Zhiming
Antengene Corporation

Recruiting

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

DLBCL Germinal Center B-Cell Type

China
GenMont Biotech Incorporation
Biomedical Development Corporation

Completed

the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis (PAR)

Probiotics | Perennial Allergic Rhinitis | Lactobacillus Paracasei GMNL-32 (eN-Lac®)

Taiwan
Boston Scientific Corporation
Guidant Corporation

Completed

Septal - Success Rate and Clinical Outcome of Septal Implant of Ventricular Defibrillation Lead

Ventricular Fibrillation | Ventricular Tachycardia

France
Boston Scientific Corporation
Guidant Corporation

Completed

Shockless Implant Evaluation (SIMPLE)

Ventricular Fibrillation | Ventricular Tachycardia

Germany, Spain, Canada, Israel, Netherlands, France, Finland, United Kingdom, Austria, Malaysia, Thailand, Hong Kong, Sweden, Hungary, Australia, Czechia, Norway, Poland
Boston Scientific Corporation
Guidant Corporation

Completed

Feature Assessment Study for Indications Based Programming (FASt-IBP)

Heart Failure | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Flutter

Germany, Spain, Switzerland, China, Austria, Belgium, France, Greece, Latvia, Netherlands, Slovakia
Boston Scientific Corporation
Guidant Corporation

Completed

Japanese Assessment of Indication Based Programming (JASMINE)

Heart Failure | Arrhythmias, Cardiac

Japan
Boston Scientific Corporation
Guidant Corporation

Completed

Quick ICD Study: Is Extensive Electrophysiological Testing Before, During and After ICD-Implantation Still Necessary ? (Quick ICD)

Cardiac Arrest

Germany
Rgene Corporation
American BriVision Corporation

Not yet recruiting

Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy

Nonsquamous Nonsmall Cell Neoplasm of Lung

Taiwan
Rgene Corporation
American BriVision Corporation

Not yet recruiting

A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer

Pancreatic Cancer
Boston Scientific Corporation
Guidant Corporation

Terminated

MODULA Modul 7 VRR

Atrial Fibrillation

Germany
Boston Scientific Corporation
EKOS Corporation

Completed

ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism (ULTIMA)

Submassive Pulmonary Embolism

Germany, Switzerland
Boston Scientific Corporation
EKOS Corporation

Completed

Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism (OPTALYSE PE)

Pulmonary Embolism and Thrombosis

United States, United Kingdom
Boston Scientific Corporation
EKOS Corporation

Completed

Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy (SEATTLE II)

Pulmonary Embolism | Acute Pulmonary Embolism | Pulmonary Thromboembolism | Massive Pulmonary Embolism | Sub-massive Pulmonary Embolism

United States
Boston Scientific Corporation
Guidant Corporation

Completed

MODULA Modul 5 BEAT-HF

Heart Failure

Germany
Boston Scientific Corporation
Guidant Corporation

Terminated

MODULA-Study: Modul 10: Benefit of CRT-Therapy in CRT-Patients With QRS-Complex of 120 - 150 Ms

Heart Failure

Germany
Guidant Corporation
Boston Scientific Corporation

Completed

Cognis and Teligen 100 HE and Reliance Quadripolar Defibrillation Lead (4-Site) Field Following (Cogent-4)

Heart Failure | Ventricular Tachycardia, Ventricular Fibrillation

Israel, Denmark
Boston Scientific Corporation
EKOS Corporation

Withdrawn

Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)

Coronary Artery Disease | Atherosclerosis | Peripheral Artery Disease | Chronic Total Occlusion

United States
Boston Scientific Corporation
EKOS Corporation

Completed

Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System (ACCESS PTS)

Deep Vein Thrombosis | Post-thrombotic Syndrome

United States
Guidant Corporation
Boston Scientific Corporation

Completed

Comparison of Right Ventricular Septal and Right Ventricular Apical Pacing in Patients Receiving a CRT-D Device (SEPTAL-CRT)

Ventricular Fibrillation | Ventricular Tachycardia | Systolic Heart Failure

France, Spain
Mitsubishi Tanabe Pharma Corporation
Kureha Corporation

Completed

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)

Chronic Kidney Disease

United States, France, Italy, Ukraine, Argentina, Mexico, Poland, Canada, Brazil, Russian Federation, Czechia, Puerto Rico
Mitsubishi Tanabe Pharma Corporation
Kureha Corporation

Completed

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)

Chronic Kidney Disease

United States, Poland, Ukraine, Spain, Argentina, Mexico, Canada, Brazil, Russian Federation, Puerto Rico, Germany, Czechia
Mannkind Corporation

Not yet recruiting

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension (ICoN-1)

Mycobacterium Infections, Nontuberculous | MAC Lung Disease | Treatment Refractory MAC Lung Disease

United States
Pulmonx Corporation

Recruiting

Zephyr Valve Japan Post-Marketing Surveillance

Emphysema | COPD | Severe Emphysema

Japan
Omeros Corporation

Recruiting

Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

Switzerland, Germany, Ukraine, United Kingdom
Yuhan Corporation

Recruiting

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
Incyte Corporation

Recruiting

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population (OPERA-1)

Pregnancy Related | Atopic Dermatitis

United States
Incyte Corporation

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant

Healthy Participants

Australia
Omeros Corporation

Recruiting

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

C3 Glomerulopathy | Idiopathic Immune Complex-Mediated Glomerulonephritis

Lithuania, New Zealand, Poland, Tunisia, Turkey, United Kingdom

Clinical Trials Sponsored by Antengene Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations